AbbVie Inc. Files 8-K: Director and Officer Changes
Ticker: ABBV · Form: 8-K · Filed: 2024-12-13T00:00:00.000Z
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: ABBV
TL;DR
ABBV board shakeup and comp changes filed. Watch for new exec strategy.
AI Summary
On December 11, 2024, AbbVie Inc. (ABBV) filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key personnel. Specific details regarding the individuals involved and the exact nature of the compensation changes are outlined within the report.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or future performance expectations.
Risk Assessment
Risk Level: low — This filing primarily concerns corporate governance and executive appointments, which typically carry a low direct financial risk.
Key Players & Entities
- AbbVie Inc. (company) — Filer of the 8-K report
- ABBV (company) — Ticker symbol for AbbVie Inc.
- 1234 (date) — Date of report filing
- 1234 (date) — Earliest event date
FAQ
Who are the specific directors or officers departing from AbbVie Inc. as reported in this 8-K?
The filing indicates the departure of certain officers and directors, but specific names are not provided in the summary information.
What are the key changes in compensatory arrangements for AbbVie's officers?
The 8-K mentions updates to compensatory arrangements for certain officers, but the specific details of these changes are not elaborated in the provided summary.
When was this 8-K report filed with the SEC?
This 8-K report was filed on December 13, 2024.
What is the primary subject matter of this 8-K filing for AbbVie Inc.?
The primary subject matter concerns the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is AbbVie Inc.'s standard industrial classification?
AbbVie Inc.'s standard industrial classification is Pharmaceutical Preparations [2834].
From the Filing
0001104659-24-128413.txt : 20241213 0001104659-24-128413.hdr.sgml : 20241213 20241213160518 ACCESSION NUMBER: 0001104659-24-128413 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241211 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20241213 DATE AS OF CHANGE: 20241213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 241548348 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm2430950d1_8k.htm FORM 8-K false 0001551152 Common Stock, $0.01 Par Value ABBV 0001551152 2024-12-11 2024-12-11 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-12-11 2024-12-11 0001551152 exch:XCHI us-gaap:CommonStockMember 2024-12-11 2024-12-11 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2024-12-11 2024-12-11 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2024-12-11 2024-12-11 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2024-12-11 2024-12-11 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2024-12-11 2024-12-11 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2024-12-11 2024-12-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549     FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): December 11, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter)   Delaware   001-35565   32-0375147 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)         1 North Waukegan Road North Chicago , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)    Registrant’s telephone number, including area code: ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange 2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange 2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange 2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange 1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emergi